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Pigs were exposed to three passages of the NADC-8 strain of porcine reproductive and respiratory syndrome virus (PRRSV) to investigate
the relationship between genotypic and phenotypic properties. Differences were found in the virulence of the three passages called virulent,
intermediate, and avirulent. Avirulent virus was derived by attenuation of virulent virus in cell culture and intermediate virus was derived by
passage of avirulent virus in a pig. Nucleotide sequence differences between virulent and avirulent virus consisted of 50 nucleotide changes
and a three-nucleotide deletion, and between avirulent and intermediate virus consisted of 8 nucleotide changes resulting in six amino acid
changes. Three of these amino acid changes were direct reversions to virulent virus. Genetic changes, especially those seemingly associated
with attenuation followed by some degree of reversion to virulence, in ORF1a, ORF1b, and ORF 6 regions of the genome may be involved in
the control of PRRSV replication and virulence.
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Introduction genome is organized in a 5V to 3V orientation as follows: aPorcine reproductive and respiratory syndrome (PRRS)
is a disease of swine characterized primarily by reproductive
failure in pregnant gilts and sows and respiratory tract
illness in pigs of all ages, but especially in suckling and
nursery-age pigs. The causative agent, PRRS virus
(PRRSV), was discovered in 1991 (Wensvoort et al.,
1991) and is classified as a member of the Arteriviridae
virus family in the order Nidovirales (Cavanagh, 1997)
PRRSV is an enveloped virus with a positive-sense, sin-
gle-stranded RNA genome approximately 15.1–15.5 kb
long (Meulenberg et al., 1993; Shen et al., 2000). The0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.01.001
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E-mail address: grebennikova@narvac.com (T.V. Grebennikova).5Vcapped structure, 5Vnon-translated leader sequence, open
reading frames (ORFs) 1a, 1b, 2–7, 3Vnon-translated region,
and a polyadenylated tail. ORF1a and 1b are overlapping
and comprise about 80% of the genome. They are believed
to encode nine and four nonstructural proteins (Nsp),
respectively, involved with viral replication and transcrip-
tion (Allende et al., 1999; Meulenberg et al., 1993; Nelsen et
al., 1999). The remaining genome, ORFs 2–7, encodes the
PRRSV structural proteins. The structural proteins are
translated from a nested set of 3V coterminal subgenomic
mRNAs.
Genetic analysis of PRRSV isolates has revealed two
predominant genotypes, the European and North American
genotypes. Based on data from the original European and
North American prototype PRRSV isolates, there was 55–
80% homology at the nucleotide level for various structural
genes (Murtaugh et al., 1995). Analysis of additional
Table 1
In vivo comparison of NADC-8 PRRSV strain passages (2), (251), and
(252P)
Group* Experiment day
3** 10 17 35
(A) Virus isolation
Sham 0/4 (0.0) 0/4 (0.0) 0/4 (0.0) 0/4 (0.0)
(251) 0/4 (0.0) 0/4 (0.0) 0/4 (0.0) 0/4 (0.0)
(252P) 1/4 (0.4) 1/4 (0.2) 2/4 (0.9) 0/4 (0.0)
(2) 3/4 (2.8) 4/4 (3.6)a 3/4 (3.0) 0/4 (0.0)
(B) Serology
Sham 0/4 (0.000) 0/4 (0.000) 0/4 (0.000) 0/4 (0.000)c
(251) 0/4 (0.000) 0/4 (0.000) 0/4 (0.000) 0/4 (0.000)c
(252P) 0/4 (0.000) 0/4 (0.000) 1/4 (0.317) 3/4 (0.850)b,c
(2) 0/4 (0.000) 3/4 (0.904)a 4/4 (0.766) 4/4 (1.280)a,b
*Each group of pigs (n = 16) on experiment day 0 was exposed to sham
inoculum, passage (251) virus, passage (252P) virus, or passage (2) virus.
Four pigs from each group were euthanized on Experiment Days 3, 10, 17,
and 35 and their serum tested for PRRSV (A) and PRRSV-specific antibody
(B). No PRRSV nor antibody were detected in Day 0 serum samples from
any pig (data not shown).
**Experimental day pigs necropsied. (A) Number of pigs positive for virus/
number of pigs tested for virus (mean virus titer  log10). (B) Number of
pigs positive for PRRSV antibody/number of pigs tested for antibody.
Positive determined as ELISA S/P ratio z0.4, (mean S/P ratio). Superscript
letter denotes statistical difference among groups on a specific day, for
example, a is different from b which is different from c.
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more homogenous as a genotype than the North American
PRRSV isolates (Le Gall et al., 1998; Mardassi et al., 1995;
Meng et al., 1995; Suarez et al., 1996). However, recent
studies have revealed more and more genetic heterogeneity
in European PRRSV isolates that may be attributed to more
extensive testing of isolates from a larger geographic region
(Forsberg et al., 2002; Indik et al., 2000; Stadejek et al.,
2002) and to the introduction of a North American PRRSV
isolate (an attenuated PRRSV vaccine) (Madsen et al.,
1998).
In 1996, a PRRSV vaccine program was initiated in
Denmark for the control and prevention of PRRS (Botner et
al., 1997). The vaccine used was a commercially available
attenuated-virus vaccine derived from a North American
field isolate that was attenuated by repetitive passage in cell
culture (Yuan et al., 2001). Following the implementation of
the vaccination program, epizootics of PRRS-like disease
were reported in some of the vaccinated herds and PRRSV
was isolated from clinically affected swine. In some cases,
genetic analysis indicated the PRRSV was closely related to
the vaccine virus (North American genotype) and not the
Danish field viruses (European genotype) (Madsen et al.,
1998). Subsequent studies demonstrated the vaccine-like
PRRSV isolates were pathogenic (Nielsen et al., 2002).
Collectively, this evidence supports the theory that the
attenuated PRRSV vaccine virus had mutated following
replication in swine and this swine-passaged vaccine virus
had gained virulence. Common genetic changes were found
among several Danish vaccine-like PRRSV field isolates
when the nucleotide sequence of the structural genes were
determined (Nielsen et al., 2001; Storgaard et al., 1999).
Some of these changes involved a nucleotide change that
lead to a ‘‘reversion’’ from the sequence of the attenuated
virus vaccine to that of the wild-type parental PRRSV.
These changes are presumed to be related to the reported
increased virulence of the vaccine-like PRRSV isolates.
Additional studies reporting full-length genomic sequences
have been completed that strived to relate genetic changes to
virulence. One report compared the vaccine nucleotide
sequence with its parental strain, VR-2332 (Yuan et al.,
2001), and a second report compared the nucleotide se-
quence of a virulent field isolate, believed to be vaccine
related, with the vaccine (Allende et al., 2000). Although
genetic differences were found in both studies, there was no
apparent common denominator that related genetic change
with virulence.
In the study reported here, we investigated further the
relationship of genetic change and virulence through a series
of in vitro and in vivo experiments. A wild-type PRRSV
was rendered avirulent by 251 passages in cell culture and
then this virus was passed in a pig in an attempt to force a
reversion of the attenuated virus to a more virulent state.
The genetic changes associated with attenuation of the
PRRSV strain and the partial reversion to virulence of this
strain are reported. The relationship of the genetic changesto attenuation and reversion and the similarities of these
genetic changes to what has been previously reported are
discussed.Results
Animal inoculations
Based on previously described animal studies (see Mate-
rials and methods), there appeared to be in vivo phenotypic
differences among the three different passages of the
NADC-8 PRRSV strain. The objective of the animal study
was to compare the virulence of these three passages under
like conditions. Passage level 2 virus [NADC-8 (2)] was
believed to be more virulent than the NADC-8 (252P) virus,
and the NADC-8 (251) virus was considered the least
virulent of the three. No PRRSV, PRRSV-specific antibody,
or clinical disease was detected in Group 1, the sham-
inoculated controls, and in Group 2, the group inoculated
with the (251) virus (Table 1). In contrast, virus and virus-
specific antibody were detected in Group 4 pigs, the pigs
inoculated with the NADC-8 (2) virus. In addition, moder-
ate clinical disease consisting of mild dyspnea and intermit-
tent anorexia and listlessness was observed in some or all of
the pigs from day 3 through about day 10 of the experiment.
Results from Group 3, pigs inoculated with the (252P) virus,
were intermediate in that virus and virus-specific antibody
were detected in some of the pigs and no clinical disease
was observed. When compared under similar conditions, the
Table 2
Summary of all nucleotide and amino acid changes among passages 2, 251, and 252P of PRRSV strain NADC-8
Gene Protein Nucleotide NADC-8 (2) NADC-8 (251) NADC-8 (252P)
position
N AA N AA N AA
ORF1a Nsp1 755 G D A N
801 G R A H
837 A E A E G G
840 G G G G T V
Nsp2 1628 A I G V
1877 A E G G
1978 C H Y(T/C) H
2042 R(G/A) E/K G E
2341 G L G L
2504 G D A N
2607 A N C T
2740 G P A P
2800 T D C D
3166 C D Y(T/C) D
3245 G A A T
3763–3765 TTA L Deletion Deletion Deletion Deletion
3767 T F A L
3914 T L C L
Nsp3 4379 T C C C
4709 C V T V
4777 G R A K
5021 G A A T
5222 T D C D
Nsp4 5825 G R G R D(C/A) P/Q
Nsp5 6324 G E A E
6357 T F C S T F
Nsp7 7300 G V A I
Nsp8 7563 T L C L
ORF1b Nsp9 8946 C H T Y
9061 C S C S T S
9306 A T G A
9363 G V C L
9735 C P T S C P
Nsp10 9909 G V T F
10,039 G R A K
10,207 T V C A
10,211 C P T P
10,650 A K G E
Nsp11 11,354 A G A G
Nsp12 12,012 T Y C H
ORF2 GP2 12,090 G L T F
12,333 T T C T T T
ORF3 GP3 13,031 C F T F
13,397 A A T A
ORF4 GP4 13,397 A N T Y
13,697 A M G V
13,762 A S T C
ORF5 GP5 13,779 T L C L
14,020 C L T L
14,102 A S T C
14,161 G L A L
14,180 T Y C H
14,317 T L A L
ORF6 M 14,440 A T G A A T
14,467 G V A I
14,662 T L C L
ORF7 N 15,050 A T G A
15,225 T V C A
15,227 A T G A
15,227 A T G A
N = nucleotide; AA = amino acid.
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8 (252P) virus and the NADC-8 (251) virus was the least
virulent.
Genomic sequencing
We hypothesized the in vivo phenotypic differences
observed in the animal study were related to genetic differ-
ences among the three passages of the NADC-8 PRRSV
strain. To test this hypothesis, the entire genomes were
obtained as overlapping PCR products and directly se-
quenced on both strands with three to six times overlap.
For each terminus, 15 independent PCR products were
cloned and sequenced. For the sake of this paper, the
nomenclature describing PRRSV genomic organization
and properties will follow the convention of others (Allende
et al., 1999; Nelsen et al., 1999; Snijder and Meulenberg,
1998; Wooten et al., 2000; Yuan et al., 2001). In all three
NADC-8 passages, there were two large ORFs, ORF1a and
ORF1b, located immediately downstream of the 5VNCR. In
the ORF1a–ORF1b frameshift region, the heptanucleotide
‘‘slippery’’ sequence (5V-UUUAAAC-3V) was present in each
passage of the NADC-8 virus in the region 7677–7683, four
nucleotides upstream of the UAG stop codon of ORF1a.
ORFs 2–7 were located downstream of the ORF1b, fol-
lowed by a 3VNCR and poly(A) tail. No changes were found
in 5Vand 3Vnoncoding regions of the three NADC-8 passages.
Nucleotide sequence differences between passages 2 and
251 consisted of 50 nucleotide changes and a three-nucle-
otide deletion (Table 2). Twenty mutations were silent and
thirty mutations resulted in predicted amino acid changes.
No nucleotide changes were found in the predicted Nsp4
and Nsp 6 cleavage product of ORF1a. The mutations in
ORF1a resulting in predicted amino acid changes were in
Nsp1, Nsp2, Nsp3, Nsp5, and Nsp7 cleavage products and
only a silent mutation was detected in the Nsp8 cleavage
product. There is no mutation in Nsp4 between passages 2
and 251. The three-nucleotide deletion in ORF1a (nucleo-
tide positions 3763–3765) resulted in the loss of a leucine in
Nsp2 cleavage product. The nucleotide changes in ORF1b
resulted in amino acid changes in Nsp9, Nsp10, and Nsp12
cleavage products. There is no mutation in Nsp11 between
passages 2 and 251. There are 17 mutations in the structuralTable 3
Nucleotide and amino acid changes found between passages 251 and 252p




ORF1a 837 Nsp1 A glutamic acid
ORF1a 840 Nsp1 G glycine
ORF1a 5825 Nsp4 G arginine
ORF1a 6357 Nsp5 T phenylalanine
ORF1a 9061 Nsp9 C serine
ORF1b 9735 Nsp10 C proline
ORF2 12,333 GP2 T threonine
ORF6 14,440 M A threoninegenes ORFs 2–7. Both nucleotide changes in ORF3 as well
as six additional mutations in ORFs 2 and 4–7 were silent.
One or more predicted amino acid changes were predicted
for gp2, gp4, gp5, M, and N proteins.
Nucleotide sequence differences between passages 251
and 252p consisted of eight nucleotide changes (Tables 2
and 3). Two of these mutations at positions 9061 (ORF1a)
and 12333 (ORF2) were silent. Three of these nucleotide
changes at positions 6357 (ORF1a), 9735 (ORF1b), and
14440 (ORF6) led to predicted amino acid changes in Nsp5,
Nsp10, and M proteins, respectively. They were direct
reversions to genotype NADC8-2. The remaining three
nucleotide changes at positions 837, 840, and 5825 (all in
ORF1a) were new mutations that produced predicted amino
acid changes in Nsp1 and Nsp4 proteins.
Sequencing of the overlapping PCR fragments provided
a ‘‘consensus’’ genomic sequence that was not dependent on
individual mutations in the minor fractions of the viral
genomic pool and PCR products. However, in some instan-
ces, nucleotide positions were difficult to deduce and are
recorded as mixed results in Table 2, that is, nucleotide
positions 1978, 2042, 3166, and 5825. This difficulty may
be attributed to a mixture of nucleotides at one position, thus
supporting the concept of PRRSV quasi-species.Discussion
In this study, the full-length nucleotide sequence of the
NADC-8 PRRSV strain, passages 2, 251, and 252P, were
compared and animal studies demonstrated that the passage
2 virus was the most virulent, passage 251 virus the least
virulent, and passage 252P had an intermediate virulence.
The first two viruses were passed in cell culture 2 and 251
times each, respectively. Pigs inoculated with the NADC-
8 (2) virus developed mild to moderate clinical disease
similar to previous studies in which pigs were exposed to
NADC-8 (3) virus, virus that had been passed three times in
cell culture (Lager et al., 1997, 1999; Mengeling et al.,
1996). In addition, the magnitude and duration of virus
replication in these pigs was also similar to the previous
studies. In contrast, pigs inoculated with the NADC-8 (251)
virus did not develop any clinical disease nor was there anyNADC8-251 NADC8-252p
Nucleotide Amino acid Nucleotide Amino acid
A glutamic acid G glycine
G glycine T valine
G arginine D(C/A) proline/glutamine
C serine T phenylalanine
C serine T serine
T serine C proline
C threonine T threonine
G alanine A threonine
Table 4
Number of mutations acquired by the PRRSV strains NADC-8 and VR-






parent and attenuated virus
NADC-8 VR-2332 NADC-8 VR-2332
5V-UTR 0a 2b 100a 99.5b
ORF1a 22 15 99.7 99.8
ORF1b 11 13 99.7 99.7
ORF2 1 4 99.9 99.5
ORF3 2 4 99.7 99.1
ORF4 3 2 99.7 99.6
ORF5 6 2 99.0 99.7
ORF6 2 3 99.6 99.4
ORF7 3 0 99.2 100
3V-UTR 0 0 100 100
a Data from the NADC-8 PRRSV strain of PRRSV.
b Data from the VR-2332 PRRSV strain (Yuan et al., 2001).
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none of the pigs became infected following oronasal inoc-
ulation with 2 104 CCID50 virus. The possibility that none
of the pigs became infected is supported by previous
studies. In one experiment, two of six pigs apparently did
not become infected following intramuscular injection of 2
 106 CCID50 NADC-8 (251) PRRSV (Mengeling et al.,
2003). This phenomenon was observed in two additional
treatment groups in that experiment in which one of six pigs
that received NADC-9 (251) and one of six pigs that
received NVSL-14 (251) apparently did not become
infected following a similar intramuscular injection of
highly attenuated PRRSV. Although four, five, and five
pigs did become infected with NADC-8 (251), NADC-9
(251), and NVSL-14 (251) PRRSV, respectively, none of
them developed clinical signs of disease and all of them
seroconverted. In a separate series of animal studies, some
fetuses (50–90 days of gestational age) were apparently not
infected with the NADC-8 (251) virus following direct
intramuscular injection or intraamniotic injection of the
fetus with about 1  103 CCID50 virus (Lager and Butler,
2002; unpublished observations). However, some fetuses
were infected and they appeared normal despite replication
of the virus.
The NADC-8 (252P) PRRSV used in this study was
derived from a pig that was subclinically infected with the
NADC-8 (251) PRRSV (unpublished observations). The pig
was inoculated with approximately 2  106 CCID50 NADC-
8 (251) PRRSV at about 4 weeks of age. PRRSV was
isolated from blood collected 28 days after inoculation.
Because this virus had been replicating in the pig for 28
days, we hypothesized that when compared to the NADC-
8 (251) passage, this virus may have an increased propensity
to replicate in pigs or an increase in virulence. This
supposition was confirmed in the animal experiment
reported here.
In the previously described animals studies, the same
source herd was used for the pigs and pregnant sows. All of
the pigs were of a similar age, health status, and genetics
(Yorkshire  Chester White cross) although they were
purchased at different times. Perhaps this temporal effect
might explain the apparent lack of infectivity found in the
present study for the NADC-8 (251) PRRSV. However, a
dose effect or route of administration may be a more
probable explanation as to why the 16 pigs oronasally
exposed to 2  104 CCID50 virus apparently did not become
infected although most pigs intramuscularly exposed to 2 
106 CCID50 virus did become infected.
Terminal parts of the viral genome are usually crucial for
replication and transcription of viral RNA and are highly
conserved 5Vand 3Vregions (Boyer and Haenni, 1994; Klump
et al., 1990; Sarnow, 1989). This was the case for the three
passages of the NADC-8 strain. No nucleotide changes were
found in the 5Vand 3Vends of the three NADC-8 passages,
even after 251 passages in cell culture and replication in a
pig for 4 weeks. Based on previous reports comparing anattenuated PRRSV with its wild-type parental virus (Allende
et al., 2000; Yuan et al., 2001), genetic differences were
anticipated between passages 2 and 251 viruses. In this
PRRSV attenuation model using the NADC-8 strain, 50
nucleotide mutations and a three-nucleotide deletion were
found between passages 2 and 251 viruses (Table 2). This
mutation rate is somewhat similar to the mutation rate
reported for the wild-type PRRSV that was attenuated by
repetitive cell culture passage and used as a commercially
available vaccine. In that case, when the attenuated virus
was compared to the parental virus there were 44 nucleotide
changes detected after 70 in vitro passages (Yuan et al.,
2001). When the location of mutations in these two exam-
ples of attenuation of wild-type PRRSV by cell culture
adaptation are examined, there is no obvious site in the
genome associated with attenuation. As might be expected
for a random incidence of mutation, there would be more
mutations in larger ORFs when compared to smaller ORFs.
This proportionate incidence of mutation was found in this
study with the NADC-8 strain and with the attenuation of
VR-2332 into a vaccine strain (Yuan et al., 2001) (Table 4).
Although the mutations appear random, it is assumed that
one or more of them relate to the attenuation process.
In an attempt to locate a mutation site that may relate to
the attenuation process, the least virulent virus, the 251st
passage, was propagated in a pig with the anticipation that
any mutations occurring during the pig passage might be
related to a loss of attenuation, that is, an increase in
virulence. When comparing the nucleotide sequences of
passages 251 and 252P, there were 8 nucleotide differences
(Tables 2 and 3). Six of these led to amino acid changes, 3
of which were revertants to the wild-type genotype. The
two nucleotide changes that did not result in an amino acid
change were in ORF1a and ORF2. Five mutations result-
ing in amino acid changes were in ORF1a and ORF1b. In
ORF1a mutations at positions 837, 840, 5825, and 6357,
resulted in deduced amino acid changes in Nsp1, 1, 4, and
5, respectively. Nsp1 has two papain-like protein domains
T.V. Grebennikova et al. / Virology 321 (2004) 383–390388(a and h). The mutation in 837 and 840 nucleotide
positions resulted in amino acid changes in Nsp1h
domains containing a putative papain-like cysteine prote-
ase. The mutation in 5825 nucleotide position is located
between the sequence of predicted chymotrypsin-like ser-
ine protease cleavage sites in Nsp4. The mutation in 6357
nucleotide position is located close to the chymotrypsin-
like serine protease cleavage sites of Nsp5 protein. In
ORF1b mutation in position 9735 resulted in a deduced
amino acid change in Nsp10, a protein containing the zinc-
finger and helicase domains. The remaining mutation was
at position 14440 in ORF 6 resulting in an amino acid
change in the predicted membrane-spanning region (amino
acid 18-34) of the membrane or M protein. The predicted
amino acid changes in Nsp5, Nsp10 and M proteins were
all revertants to the original wild-type virus sequence, the
NADC-8 (2) virus.
Although there are many reports describing complete and
partial genomic sequences of PRRSV strains, there are only a
few that analyze the mutations associated with attenuation of
PRRSV and the reversion of attenuated PRRSV to a more
virulent state. The incidence and clustering of mutations in
ORF1 associated with reversion to virulence found in this
study have been observed before when vaccine-derived field
PRRSV isolates were sequenced and compared with the
vaccine parental strain, VR-2332 (Nielsen et al., 2001).
Two reversions to the VR-2332 genotype were consistently
found in these field isolates: one was in the papain-like
cysteine protease domain of Nsp1b, and the other one in the
helicase domain of the Nsp10 protein. In addition, the
reversion in ORF 6 found in this study supports observations
by others who associated mutations in ORF 6 with a
reversion to virulence (Madsen et al., 1998). A full-length
genetic analysis of a virulent PRRSV field isolate (16244B)
revealed that at the nucleotide level, it has about 98%
homology with the VR-2332 PRRSV strain and the attenu-
ated vaccine derived from VR-2332 (Allende et al., 2000).
Based on this work, it is proposed that the 16244B virus is a
descendent of the vaccine and genetic differences between
the 16244B and the vaccine virus could reflect mutations in
vaccine virus that led to a reversion to virulence. Mutations
were identified in ORFs 1a (Nsp1b, Nsp2) and 1b (Nsp1, 2,
3, 5, and 6) that may have contributed to a reversion to
virulence. However, the exact origin of the 16244B virus is
not clear which may cast doubt on the linkage between these
specific mutations and a reversion to virulence (Yuan et al.,
2001).
Collectively, this study and the work of others suggest
that mutations in Nsp1, Nsp10, and M protein may be
related to the attenuation of PRRSV by repetitive passage
in cell culture. Confirmation of this assumption awaits the
necessary experiments utilizing a reverse genetics system
for PRRSV. Additional mutations between passages 251and
252p viruses were found in this study and, as in other
studies, the influence of these mutations on PRRSV viru-
lence is not known.Materials and methods
Virus
The NADC-8 strain of PRRSV used in this study was
isolated from the serum of a weak-born congenitally infected
pig (Lager et al., 1997). Selection of each virus passage used
for experimental inoculation of pigs was based on the relative
reported or presumed virulence, mainly the degree of repli-
cation in pigs and cell cultures. Passage level 2 had been
passaged once in cell culture following its initial isolation in
cell culture. Although limited animal studies have been
conducted with the second passage of NADC-8 PRRSV, it
is assumed to be virulent based on extensive studies with the
third passage of NADC-8 PRRSV (Lager et al., 1997, 1999;
Mengeling et al., 1996). Passage level 251 was derived from
passage level 2 by an additional 249 passages in cell culture.
Passage level 251 was highly attenuated producing limited if
any clinical effects in infected pigs (Mengeling et al., 2003).
Sometimes pigs did not become infected even when passage
251 was administered intramuscularly at a dose of 2  106
median cell culture infectious doses (CCID50) (Mengeling et
al., 2003). Passages 3–13 were made at 3- or 4-day intervals
in either 75 cm2 tissue culture flasks or 24-well tissue culture
plates. Between passages 14 and 249, the virus was passaged
in 24-well plates at daily intervals at or near the maximum
dilution that resulted in infection of the next culture in the
passage series. The maximum dilution was identified in
retrospect from among several dilutions made at each pas-
sage. Because the efficiency of virus replication in cell culture
increased with passage level, the passage dilution (i.e., the
dilution of medium from the previous culture) ranged from
1:5 for early passages to 1:50,000 for late passages. The
indicated dilution was based on the final dilution of inoculum
in the medium of the culture to which the inoculum was
added. Passage level 252P was derived from passage level
251 by infecting a pig with an aliquot of the 251st cell culture
passage, collecting a virus-containing serum sample 28 days
later (presumably enough time to allow 84 cycles of virus
replication in the pig), and then passing that sample (virus
population) once more in cell culture. We presumed that
passage level 252P might be more virulent than passage level
251 because the 252P virus had replicated in a pig for 4 weeks
and this virus might have accumulated mutations that would
promote viral replication in vivo.
Viral inocula were prepared by freezing and thawing the
virus-infected cell culture when approximately 50% cyto-
pathic effect was visible. The cell lysate was clarified,
titrated, and the inoculum was diluted to provide a virus
solution containing 1  104 CCID50/ml. A sham or mock-
infected cell culture lysate was prepared in a similar fashion.
Animal study
An animal study was conducted to compare the virulence
of the three passages of the NADC-8 PRRSV strain under
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old crossbred piglets (Yorkshire  Chester White) were
randomly divided into four treatment groups, 16 pigs to a
group. Each treatment group was housed individually in
animal isolation facilities at the National Animal Disease
Center. On Day 0, Groups 1, 2, 3, and 4 received a 2-ml
oronasal inoculation of the sham, (251), (252P), and (2)
passages of the NADC-8 PRRSV strain, respectively. Four
pigs out of each treatment group were euthanized on
experiment days 3, 10, 17, and 35 with an intravenous
injection of pentobarbital. Blood was collected from all pigs
on days 0, 3, 10, 17, and 35. For the purposes of this study,
the virulence of each virus passage was based on the
magnitude and duration of virus replication and serocon-
version in the inoculated pigs. Each serum sample was
tested by virus isolation (Lager et al., 1997) and for the
presence of PRRSV antibodies using a commercially avail-
able ELISA (IDEXX, USA). Virus titer was determined for
virus-positive serum samples and the mean values for virus
titer and ELISA tests were compared using ANOVA. A P
value V0.05 was considered significant. The pigs were
observed daily for overt signs of illness, that is, anorexia,
listlessness, and dyspnea.
Cells, RNA isolation, and amplification of PRRSV genome
The following methods were used for all three passages
of the NADC-8 PRRSV strain that were used as inoculum
and sequenced. The MARC-145 cell culture was used for
isolation and propagation of the virus (Kim et al., 1993).
The cells were cultured in Earl’s minimum essential medi-
um, supplemented with 10% fetal bovine serum and 50 mg/
ml gentamicin sulfate in a humidified 5% CO2 atmosphere
at 37 jC. Total RNAwas isolated from monolayers of virus-
infected cells with TRIzol reagent (Life Technologies)
according to the manufacturer’s specification.
Reverse transcription and polymerase chain reaction
(RT-PCR) were carried out with reverse transcriptase and
TaqI polymerase (Life Technologies) as previously de-
scribed (Sellner et al., 1994) using 151 specific primers.
Primers were designed based on published sequences of
PRRSV genomes found under the following Genbank
accession numbers: AF046869 (PRRSV strain 16244B),
AF030244, and U00153 (PRRSV strain VR-2332). The
GC content of the primers was 45–53%, they were 17 and
18 nucleotides long, and intervals between primers on the
opposite strands were approximately 100–150 nucleotides.
All RT-PCR primer sequences are available from the
authors on request. Amplifications were carried out in
100 Al volume containing 1 Ag of RNA, 100 pmol of
each primer, 5 U of TaqI polymerase, 2.5 U MMLV-RT, 10
mM Tris–HCl, (pH 9.0 at 25 jC), 50 mM KCl, 0.1%
Triton X-100, 1.5 mM MgCl2. Reverse transcription was
carried out for 60 min at 50–53 jC followed by a 5-min
holding period at 94 jC. Amplification was carried out for
30 cycles (30 s at 94 jC, 30 s at 51–53 jC, 2 min at 72jC). PCR products of the 3V and 5V ends of the NADC8
genome were obtained using a 3V RACE and 5VRACE
Systems for Rapid Amplification of cDNA ends (Life
Technologies).
Sequence analysis
Overlapping PCR products for each virus covering the
entire genome were gel-purified using Geneclean PCR
purification kits (Geneclean) and directly sequenced using
PRIZM FS reagents (Perkin Elmer). The sequencing
reactions were run and analyzed in an automated sequenc-
er (ABI 377, USA). Sequences were aligned and analyzed
using MacVector/AssemblyLign (Oxford Molecular
Group, USA).References
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